BioCheck Inc Acquires DRG International Inc, a leading IVD company
PR91212
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 /PRNewswire=KYODO JBN/ --
-- Transformative deal significantly increases IVD development, manufacturing
and sales channel for novel ELISA and Chemiluminescent immunoassay platforms
BioCheck, Inc. (https://c212.net/c/link/?t=0&l=en&o=3263650-1&h=2004886458&u=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttp%253A%252F%252Fwww.perkinelmer.com%26esheet%3D52465436%26newsitemid%3D20210726005241%26lan%3Den-US%26anchor%3DPerkinElmer%252C%2BInc.%26index%3D1%26md5%3D5c6d80a1d3faf6cb9cbd2ea6178a928d&a=BioCheck%2C+Inc.) has announced that it has acquired DRG International, a leading manufacturer of clinical diagnostic and research ELISAs with distributors in over 110
countries. DRG is also the manufacturer of the DRG:HYBRiD-XL(R), a fully
automated analyzer for Immunoassays and Clinical Chemistry. DRG International,
Inc. operates in accordance with the FDA 21 CFR 820 Quality System Regulation
as well as the ISO 13485:2016 and MDSAP (Medical Device Single Audit Program)
by TÜV Rheinland.
Roy Paxton Yih, CEO of BioCheck, Inc. said " the DRG:HYBRiD-XL(R) and
BioCheck's new automated chemiluminescent platform (ACL-Platform) will enable
us to accelerate the availability of optimized, reliable and accurate advanced
clinical and research diagnostic tests in the neurological disorders and other
diseases. Leveraging BioCheck's assay development capabilities with DRG's
development center, the combined companies are well positioned to rapidly scale
availability of current tests and develop novel IVD tests for several diseases
in the future globally to over 110 countries."
Global IVD Diagnostic Market news provided by "Research and Markets
Publication" June 8, 2021
"At an estimated value of over USD 72.02 billion in 2019, the Global In
Vitro Diagnostics (IVD) Market is predicted to thrive at a CAGR of 4.1%
and valued at over USD 112.05 billion over the forecast year 2020-2030.
"In vitro diagnostics is experiencing a significant popularity in
healthcare sector due to its efficacy in diagnosing numerous medical
conditions such as infectious diseases, cardiac disorders, cancer, and
nephrological disorders.
Upsurge in number of in vitro diagnostic tests across the globe owing
to the increased incidences of infectious and chronic diseases drives
the growth of IVD market. In addition, rise in geriatric population,
which is vulnerable to immunological disorders have been pushing the
growth of the market globally."
Yih also added "We look forward to welcoming the highly talented members of the
DRG team who bring additional R&D capabilities and manufacturing strength to
BioCheck, helping to further elevate our clinical and research IVD business."
About BioCheck, Inc.
Since 1997, BioCheck, Inc. has been engaged in the development and
manufacturing of high-quality in vitro diagnostic test kits for the worldwide
biomedical, pharmaceutical, and scientific research markets under cGMP and ISO
13485 standards. BioCheck is commercializing the (automated chemiluminescent
platform (ACL-Platform)) and associated Covid-19 and other cytokine, metabolic,
and cardiovascular test kits to allow convenient, instant, and accurate
diagnosis of disease markers with a bench top instrument. BioCheck is financed
by seasoned biotech investors Emerging Technology Partners. www.biocheckinc.com
SOURCE: BioCheck Inc
CONTACT: info@biocheckinc.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。